The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Weekly paclitaxel plus bevacizumab versus docetaxel as second or third-line treatment in advanced non-squamous non-small cell lung cancer (NSCLC): Results from the phase III study IFCT-1103 ULTIMATE.
 
Alexis B. Cortot
No Relationships to Disclose
 
Clarisse Audigier-Valette
Consulting or Advisory Role - Amgen; AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; Lilly; Novartis; Pfizer; Roche; Sysmex
Research Funding - Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Novartis (Inst); Roche; Roche (Inst)
Travel, Accommodations, Expenses - Amgen; Bristol-Myers Squibb; Lilly; Novartis; Pfizer; Roche
 
Olivier Molinier
No Relationships to Disclose
 
Sylvestre Le Moulec
No Relationships to Disclose
 
Fabrice Barlesi
No Relationships to Disclose
 
Gerard Zalcman
Honoraria - Lilly; Pfizer; Roche
Consulting or Advisory Role - Boehringer Ingelheim (Inst); Bristol-Myers Squibb; Bristol-Myers Squibb; Lilly (Inst); Pfizer (Inst); Roche (Inst)
Research Funding - AstraZeneca (Inst); Pfizer (Inst); Roche (Inst)
Travel, Accommodations, Expenses - Bristol-Myers Squibb; Lilly; Pfizer; Pfizer; Roche
 
Patrick Dumont
No Relationships to Disclose
 
Damien Pouessel
Honoraria - Amgen; Astellas Pharma; Boehringer Ingelheim; Janssen; Sanofi
Consulting or Advisory Role - Astellas Pharma; AstraZeneca; Lilly; MSD Oncology; Novartis; Roche; Sanofi
Research Funding - Amgen (Inst); MSD Oncology (Inst); Oncogenex (Inst); Roche (Inst)
Travel, Accommodations, Expenses - Novartis; Sanofi
 
Claire Poulet
No Relationships to Disclose
 
Pierre Jean Souquet
Honoraria - AstraZeneca; Bristol-Myers Squibb; Roche
Consulting or Advisory Role - Lilly/ImClone; PFIZER; Roche/Genentech
Speakers' Bureau - Amgen; AstraZeneca; boehringer ingelheim; Lilly/ImClone; pfizer; Roche/Genentech
Research Funding - AstraZeneca; Boehringer Ingelheim; Clovis Oncology; GlaxoSmithKline; LILLY (Inst); Novartis; Roche/Genentech (Inst)
Travel, Accommodations, Expenses - LILLY; PFIZER
 
Sandrine Hiret
Honoraria - Boehringer Ingelheim; Roche
Consulting or Advisory Role - AstraZeneca
Travel, Accommodations, Expenses - Roche
 
Adrien Dixmier
Honoraria - AstraZeneca; Roche
Consulting or Advisory Role - Bristol-Myers Squibb; MSD; Novartis
 
Patrick-Aldo Renault
No Relationships to Disclose
 
Alexandra Langlais
No Relationships to Disclose
 
Marie Paule Lebitasy
No Relationships to Disclose
 
Franck Morin
No Relationships to Disclose
 
Denis Moro-Sibilot
No Relationships to Disclose
 
Benjamin Besse
Research Funding - AstraZeneca (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Clovis Oncology (Inst); GlaxoSmithKline (Inst); Inivata (Inst); Lilly (Inst); Onxeo (Inst); ose pharma (Inst); Pfizer (Inst); Puma Biotechnology (Inst); Roche/Genentech (Inst); SERVIER (Inst)
Travel, Accommodations, Expenses - Bristol-Myers Squibb/Medarex; Novartis; Pfizer; Pierre Fabre; Roche